Ena Respiratory: Funding, Investors & Team (Sep 2026)
Ena Respiratory is a biotechnology company focused on revolutionizing the way respiratory infections are treated and prevented, as well as improving the efficacy of vaccines. Their innovative synthetic Toll-like receptor 2 (TLR2) agonists have demonstrated the ability to stimulate the innate immune system in the respiratory tract, thereby halting the spread of viruses and bacteria to the lungs.
Ena Respiratory has raised $56.0M across 4 funding rounds on record, the most recent a Series B of $22.4M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ena Respiratory Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Ena Respiratory Funding Rounds
Ena Respiratory raised $24.2M in an undisclosed round announced in Jun 2021.
1.6 years later, an undisclosed round of $4.4M was announced in Jan 2023.
2.1 years later, an undisclosed round of $5.0M was announced in Feb 2025.
8 months later, a Series B of $22.4M was announced in Oct 2025.
Ena Respiratory Founders and Leadership Team
Contact details for the Ena Respiratory team: 1 of 1 has an email address on file.
Start 14-day free trial →Ena Respiratory Funding Compared to Other Biotechnology Startups
Ena Respiratory's latest round of $22.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ena Respiratory in Biotechnology and Melbourne
Companies Similar to Ena Respiratory
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Ena Respiratory Funding FAQs
What does Ena Respiratory do?
Ena Respiratory is a biotechnology company focused on revolutionizing the way respiratory infections are treated and prevented, as well as improving the efficacy of vaccines. Their innovative synthetic Toll-like receptor 2 (TLR2) agonists have demonstrated the ability to stimulate the innate immune system in the respiratory tract, thereby halting the spread of viruses and bacteria to the lungs.
How much funding has Ena Respiratory raised?
Ena Respiratory has raised $56.0M across 4 rounds on record. The most recent is a Series B of $22.4M announced in Oct 2025.
When did Ena Respiratory last raise funding?
Ena Respiratory's most recent funding round on record is a Series B of $22.4M, announced in Oct 2025.
Who is the CEO of Ena Respiratory?
Christophe Demaison is listed as CEO at Ena Respiratory.
Where is Ena Respiratory headquartered?
Ena Respiratory is based in Melbourne, Victoria, Australia.
How many employees does Ena Respiratory have?
Ena Respiratory is in the 1-10 employee band.
How does Ena Respiratory's funding compare to other Biotechnology startups?
Ena Respiratory's latest round of $22.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ena Respiratory Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ena Respiratory is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.